172 related articles for article (PubMed ID: 7676541)
1. [New parameters for prediction of pathological stage in clinical stage I non-seminomatous testicular tumors].
Albers P; Ulbright TM; Albers J; Miller GA; Foster RS; Donohue JP
Urologe A; 1995 Jul; 34(4):316-23. PubMed ID: 7676541
[TBL] [Abstract][Full Text] [Related]
2. Tumor proliferative activity is predictive of pathological stage in clinical stage A nonseminomatous testicular germ cell tumors.
Albers P; Ulbright TM; Albers J; Miller GA; Orazi A; Crabtree WN; Baniel J; Reister T; Sidner RA; Foster RS; Donohue JP
J Urol; 1996 Feb; 155(2):579-86. PubMed ID: 8558664
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of immunohistochemical proliferation markers (Ki-67/MIB-1 and proliferation-associated nuclear antigen), p53 protein accumulation, and neovascularization in clinical stage A nonseminomatous testicular germ cell tumors.
Albers P; Orazi A; Ulbright TM; Miller GA; Haidar JH; Donohue JP; Foster RS
Mod Pathol; 1995 Jun; 8(5):492-7. PubMed ID: 7545814
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical expression of Ki-67 to predict lymph node involvement in clinical stage I nonseminomatous germ cell tumors.
Heidenreich A; Schenkmann NS; Sesterhenn IA; Mostofi FK; McCarthy WF; Heidenreich B; Moul JW
J Urol; 1997 Aug; 158(2):620-5. PubMed ID: 9224380
[TBL] [Abstract][Full Text] [Related]
5. Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis.
Heidenreich A; Sesterhenn IA; Mostofi FK; Moul JW
Cancer; 1998 Sep; 83(5):1002-11. PubMed ID: 9731905
[TBL] [Abstract][Full Text] [Related]
6. MIB-1 immunohistochemistry in clinical stage I nonseminomatous testicular germ cell tumors predicts patients at low risk for metastasis.
Albers P; Bierhoff E; Neu D; Fimmers R; Wernert N; Müller SC
Cancer; 1997 May; 79(9):1710-6. PubMed ID: 9128986
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial.
Albers P; Siener R; Kliesch S; Weissbach L; Krege S; Sparwasser C; Schulze H; Heidenreich A; de Riese W; Loy V; Bierhoff E; Wittekind C; Fimmers R; Hartmann M;
J Clin Oncol; 2003 Apr; 21(8):1505-12. PubMed ID: 12697874
[TBL] [Abstract][Full Text] [Related]
8. Incidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancer.
Eggener SE; Carver BS; Sharp DS; Motzer RJ; Bosl GJ; Sheinfeld J
J Urol; 2007 Mar; 177(3):937-42; discussion 942-3. PubMed ID: 17296380
[TBL] [Abstract][Full Text] [Related]
9. Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group.
Heidenreich A; Albers P; Hartmann M; Kliesch S; Kohrmann KU; Krege S; Lossin P; Weissbach L;
J Urol; 2003 May; 169(5):1710-4. PubMed ID: 12686815
[TBL] [Abstract][Full Text] [Related]
10. Primary retroperitoneal lymph node dissection in patients with clinical stage IS testis cancer.
Williams SB; Steele GS; Richie JP
J Urol; 2009 Dec; 182(6):2716-20. PubMed ID: 19836777
[TBL] [Abstract][Full Text] [Related]
11. Retroperitoneal lymph node dissection in the treatment of low-stage nonseminomatous germ cell tumors of the testicle.
Yoon GH; Stein JP; Skinner DG
Expert Rev Anticancer Ther; 2005 Feb; 5(1):75-85. PubMed ID: 15757440
[TBL] [Abstract][Full Text] [Related]
12. [Effect of biological prognostic factors on therapy of non-seminomatous stage I testicular tumors--an assessment of the current status].
Kuczyk MA; Bokemeyer C; Serth J; Machtens S; Höfner K; Jonas U
Urologe A; 1996 Jan; 35(1):35-45. PubMed ID: 8851847
[TBL] [Abstract][Full Text] [Related]
13. Surgical management of low-stage nonseminomatous germ cell testicular cancer.
Stephenson AJ; Klein EA
BJU Int; 2009 Nov; 104(9 Pt B):1362-8. PubMed ID: 19840014
[TBL] [Abstract][Full Text] [Related]
14. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome.
Stephenson AJ; Bosl GJ; Motzer RJ; Kattan MW; Stasi J; Bajorin DF; Sheinfeld J
J Clin Oncol; 2005 Apr; 23(12):2781-8. PubMed ID: 15837993
[TBL] [Abstract][Full Text] [Related]
15. Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion.
Stephenson AJ; Bosl GJ; Bajorin DF; Stasi J; Motzer RJ; Sheinfeld J
J Urol; 2005 Aug; 174(2):557-60; discussion 560. PubMed ID: 16006891
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical assessment of tumor proliferation and volume of embryonal carcinoma identify patients with clinical stage A nonseminomatous testicular germ cell tumor at low risk for occult metastasis.
Albers P; Miller GA; Orazi A; Ulbright TM; Albers J; Donohue JP; Foster RS
Cancer; 1995 Feb; 75(3):844-50. PubMed ID: 7828136
[TBL] [Abstract][Full Text] [Related]
17. Predictors of positive retroperitoneal lymph nodes in patients with high risk testicular cancer.
Williams SB; Kacker R; Winston D; Bahnson E; Steele GS; Richie JP
J Urol; 2011 Dec; 186(6):2245-8. PubMed ID: 22014805
[TBL] [Abstract][Full Text] [Related]
18. Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters?
Spiess PE; Brown GA; Pisters LL; Liu P; Tu SM; Evans JG; Kamat AM; Black P; Tannir NM
Cancer; 2006 Oct; 107(7):1503-10. PubMed ID: 16944534
[TBL] [Abstract][Full Text] [Related]
19. Laparoscopic retroperitoneal lymphadenectomy for stage I non-seminomatous testicular tumors.
Custureri F; Urciuoli P; Iavarone C; D'Orazi V; Gabatel R; Ghinassi S; Patrizi G; Palazzini G; Di Matteo FM; Peparini N
Hepatogastroenterology; 2005; 52(66):1677-80. PubMed ID: 16334755
[TBL] [Abstract][Full Text] [Related]
20. Does the presence of extranodal extension in pathological stage B1 nonseminomatous germ cell tumor necessitate adjuvant chemotherapy?
Beck SD; Cheng L; Bihrle R; Donohue JP; Foster RS
J Urol; 2007 Mar; 177(3):944-6. PubMed ID: 17296383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
